SCHEMBL6864433

SCHEMBL6864433

COc1ccc2c(c1)cc(C(=O)c1cc3ccccc3[nH]1)n2C

nearest known ligand 0.67

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 8/20 0.67
PDGFRA P16234 8/20 0.67
FLT3 P36888 4/20 0.67
L3MBTL1 Q9Y468 1/20 0.57
KDM4E B2RXH2 1/20 0.57
ALDH1A1 P00352 1/20 0.57
HPGD P15428 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
HSD17B10 Q99714 1/20 0.57
MEN1 O00255 1/20 0.56
CYP1A2 P05177 1/20 0.56
CYP3A4 P08684 1/20 0.56
CYP2C9 P11712 1/20 0.56
TSHR P16473 1/20 0.56
KMT2A Q03164 1/20 0.56
HDAC6 Q9UBN7 1/20 0.56
FGFR1 P11362 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6866896 0.91 FLT3 (0.67) PDGFRBPDGFRAFLT3MEN1CYP1A2
SCHEMBL6866879 0.85 PDGFRB (0.63) PDGFRBPDGFRAFLT3MEN1CYP1A2
SCHEMBL7685387 0.83 PDGFRB (0.60) PDGFRBPDGFRAFLT3KDM4EMEN1
SCHEMBL6865103 0.81 FLT3 (1.00) PDGFRBPDGFRAFLT3MEN1CYP1A2
SCHEMBL6864570 0.79 FLT3 (1.00) PDGFRBPDGFRAFLT3MEN1CYP1A2
SCHEMBL6331990 0.77 PDGFRB (0.72) PDGFRBPDGFRAFLT3MEN1CYP1A2
SCHEMBL6867577 0.76 FLT3 (0.63) PDGFRBPDGFRAFLT3L3MBTL1KDM4E
SCHEMBL13931838 0.76 L3MBTL1 (0.63) L3MBTL1KDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL6871064 0.74 KDM4E (0.57) L3MBTL1KDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL7065107 0.74 PDGFRB (0.71) PDGFRBPDGFRAFLT3MEN1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6812243-B2 AS TYROSINE KINASE INHIBITORS; FOR THERARPY OF TUMORS, ARTERIOSCLEROSIS, RESTENOSIS AFTER BALLOON ANGIOPLASTY, ARTHRITIS AND FIBROTIC DISEASES ZENTARIS AG (DE) 2004-11-02 US disclosed
US-20030008898-A1 Indole derivatives and their use for the treatment of malignant and other diseases based on pathological proliferation ZENTARIS AG (DE) 2003-01-09 US disclosed
US-6407102-B1 TYROSINE KINASE AND PLATELET-DERIVED GROWTH FACTOR INHIBITORS; ANTICARCINOGENIC, ANTITUMOR, ANTIARTHRITIC AND ANTIPROLIFERATIVE AGENTS; RESTENOSIS, ARTERIOSCLEROSIS ZENTARIS AG (DE) 2002-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030008898-A1 Indole derivatives and their use for the treatment of malignant and other diseases based on pathological proliferation MKI67, IDO1, CCNI PDGFRB 474/4885PDGFRA 542/4885FLT3 230/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.